{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:27:33Z","timestamp":1792132053660,"version":"4.4.0"},"reference-count":176,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"am","delay-in-days":369,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50GM115305"],"award-info":[{"award-number":["P50GM115305"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI152183"],"award-info":[{"award-number":["R01AI152183"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HG010863"],"award-info":[{"award-number":["R01HG010863"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R13AR078623"],"award-info":[{"award-number":["R13AR078623"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01AI154659"],"award-info":[{"award-number":["U01AI154659"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UAI109565"],"award-info":[{"award-number":["UAI109565"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jaip.2022.02.004","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T22:34:58Z","timestamp":1644878098000},"page":"1155-1167.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":205,"title":["Drug-Induced Hypersensitivity Syndrome (DIHS)\/Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Clinical Features and Pathogenesis"],"prefix":"10.1016","volume":"10","author":[{"given":"Natsumi","family":"Hama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riichiro","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2022.02.004_bib1","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jaip.2017.01.025","article-title":"Severe delayed cutaneous and systemic reactions to drugs: a global perspective on the science and art of current practice","volume":"5","author":"Peter","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.02.004_bib2","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1056\/NEJM195006082422304","article-title":"Dilantin sensitivity: report of a case of hepatitis with jaundice, pyrexia and exfoliative dermatitis","volume":"242","author":"Chaiken","year":"1950","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.02.004_bib3","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/j.1365-2133.2007.07807.x","article-title":"The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations","volume":"156","author":"Shiohara","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib4","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"156","author":"Kardaun","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib5","first-page":"6431694","article-title":"An updated review of the molecular mechanisms in drug hypersensitivity","volume":"2018","author":"Chen","year":"2018","journal-title":"J\u00a0Immunol Res"},{"key":"10.1016\/j.jaip.2022.02.004_bib6","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.3390\/ijms22042147","article-title":"Current perspective regarding the immunopathogenesis of drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms (DIHS\/DRESS)","volume":"22","author":"Miyagawa","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaip.2022.02.004_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.amjmed.2011.10.027","article-title":"Human herpesvirus 6 reactivation in drug-induced hypersensitivity syndrome and DRESS validation score","volume":"125","author":"Ushigome","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.jaip.2022.02.004_bib8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.alit.2019.03.006","article-title":"Drug-induced hypersensitivity syndrome (DiHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): an update in 2019","volume":"68","author":"Shiohara","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2022.02.004_bib9","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/1346-8138.12770","article-title":"Sequelae in 145 patients with drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms: survey conducted by the Asian Research Committee on Severe Cutaneous Adverse Reactions (ASCAR)","volume":"42","author":"Kano","year":"2015","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2332\/allergolint.55.1","article-title":"Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses","volume":"55","author":"Shiohara","year":"2006","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2022.02.004_bib11","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.iac.2017.07.007","article-title":"Severe delayed drug reactions: role of genetics and viral infections","volume":"37","author":"Pavlos","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2022.02.004_bib12","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1016\/j.jaip.2020.07.005","article-title":"Delabeling delayed drug hypersensitivity: how far can you safely go?","volume":"8","author":"Lehloenya","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.02.004_bib13","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaad.2021.04.020","article-title":"Discriminating minor and major forms of drug reaction with eosinophilia and systemic symptoms: facial\u00a0edema aligns to the severe phenotype","volume":"85","author":"Momen","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib14","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/ajh.26346","article-title":"Hematologic findings in drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"96","author":"Pukhalskaya","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaip.2022.02.004_bib15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaip.2017.11.023","article-title":"SJS\/TEN 2017: building multidisciplinary networks to drive science and translation","volume":"6","author":"White","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.02.004_bib16","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/ced.12682","article-title":"Drug reaction with eosinophilia and systemic symptoms\/drug-induced hypersensitivity syndrome: clinical features of 27 patients","volume":"40","author":"Avancini","year":"2015","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib17","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/1346-8138.14288","article-title":"Case of lamotrigine-induced drug adverse reaction under tocilizumab treatment with clinical and virological features of drug-induced hypersensitivity syndrome","volume":"45","author":"Iriki","year":"2018","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib18","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/1346-8138.14776","article-title":"Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms due to lamotrigine differs from that due to other drugs","volume":"46","author":"Tashiro","year":"2019","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jdermsci.2012.10.002","volume":"69","author":"Ogawa","year":"2013","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jaip.2022.02.004_bib20","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00281-021-00857-w","article-title":"What does elevated TARC\/CCL17 expression tell us about eosinophilic disorders?","volume":"43","author":"Catherine","year":"2021","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jaip.2022.02.004_bib21","first-page":"5163129","article-title":"Recent advances in drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms","volume":"2018","author":"Watanabe","year":"2018","journal-title":"J\u00a0Immunol Res"},{"key":"10.1016\/j.jaip.2022.02.004_bib22","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s40264-019-00825-2","article-title":"Mechanisms of severe cutaneous adverse reactions: recent advances","volume":"42","author":"Bellon","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaip.2022.02.004_bib23","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1146\/annurev-pharmtox-010818-021818","article-title":"Applications of immunopharmacogenomics: predicting, preventing, and understanding immune-mediated adverse drug reactions","volume":"59","author":"Karnes","year":"2019","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jaip.2022.02.004_bib24","doi-asserted-by":"crossref","first-page":"658593","DOI":"10.3389\/fimmu.2021.658593","article-title":"Characterization of T-cell responses to SMX and SMX-NO in co-trimoxazole hypersensitivity patients expressing HLA-B\u221713:01","volume":"12","author":"Pratoomwun","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2022.02.004_bib25","doi-asserted-by":"crossref","first-page":"661135","DOI":"10.3389\/fimmu.2021.661135","article-title":"HLA-B\u221713 :01 is a predictive marker of dapsone-induced severe cutaneous adverse reactions in Thai patients","volume":"12","author":"Satapornpong","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2022.02.004_bib26","doi-asserted-by":"crossref","first-page":"9959","DOI":"10.1073\/pnas.1207934109","article-title":"Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire","volume":"109","author":"Ostrov","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaip.2022.02.004_bib27","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1086\/529382","article-title":"High sensitivity of human leukocyte antigen-b\u22175701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients","volume":"46","author":"Saag","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaip.2022.02.004_bib28","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B\u22175701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.02.004_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117160","article-title":"Abacavir-reactive memory T cells are present in drug naive individuals","volume":"10","author":"Lucas","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2022.02.004_bib30","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1172\/JCI121525","article-title":"Active suppression rather than ignorance: tolerance to abacavir-induced HLA-B\u221757:01 peptide repertoire alteration","volume":"128","author":"Phillips","year":"2018","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaip.2022.02.004_bib31","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41591-019-0733-7","article-title":"Targeted therapy guided by single-cell transcriptomic analysis in drug-induced hypersensitivity syndrome: a case report","volume":"26","author":"Kim","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2022.02.004_bib32","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jaci.2019.01.045","article-title":"HLA-A\u221732:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms","volume":"144","author":"Konvinse","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.02.004_bib33","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B\u22175801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaip.2022.02.004_bib34","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.jaip.2022.02.004_bib35","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa1213096","article-title":"HLA-B\u221713:01 and the dapsone hypersensitivity syndrome","volume":"369","author":"Zhang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.02.004_bib36","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/cid\/cit021","article-title":"Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population","volume":"56","author":"Carr","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaip.2022.02.004_bib37","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/cpt.2343","article-title":"Immunopharmacogenomics: mechanisms of HLA-associated drug reactions","volume":"110","author":"Deshpande","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaip.2022.02.004_bib38","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamadermatol.2018.5360","article-title":"Evaluation of prospective HLA-B\u221713:01 screening to prevent dapsone hypersensitivity syndrome in patients with leprosy","volume":"155","author":"Liu","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF03256308","article-title":"Successful translation of pharmacogenetics into the clinic: the abacavir example","volume":"13","author":"Phillips","year":"2009","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.jaip.2022.02.004_bib40","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jaci.2020.05.050","article-title":"Pharmacogenomic biomarkers in allergy and immunology practice","volume":"146","author":"Khan","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.02.004_bib41","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00002030-200501030-00014","article-title":"Predisposition to nevirapine hypersensitivity associated with HLA-DRB1\u22170101 and abrogated by low CD4 T-cell counts","volume":"19","author":"Martin","year":"2005","journal-title":"Aids"},{"key":"10.1016\/j.jaip.2022.02.004_bib42","author":"Hollenbach"},{"key":"10.1016\/j.jaip.2022.02.004_bib43","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib44","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1016\/j.jaip.2021.05.008","article-title":"Reporting of drug reaction with eosinophilia and systemic symptoms from 2002 to 2019 in the US Food and Drug Administration Adverse Event Reporting System","volume":"9","author":"Bluestein","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.02.004_bib45","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1684\/ejd.2019.3522","article-title":"DIHS\/DRESS-like eruption possibly induced by amoxicillin during treatment with nivolumab","volume":"29","author":"Takimoto","year":"2019","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib46","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jdcr.2021.04.033","article-title":"Drug-induced hypersensitivity syndrome like reaction with angioedema and hypotension associated with BRAF inhibitor use and antecedent immune checkpoint therapy","volume":"13","author":"Rana","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaip.2022.02.004_bib47","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2147\/CMAR.S163391","article-title":"Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies","volume":"10","author":"Chen","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.jaip.2022.02.004_bib48","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jaad.2020.09.054","article-title":"Cutaneous adverse events caused by immune checkpoint inhibitors","volume":"85","author":"Quach","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib49","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jdcr.2020.08.020","article-title":"Drug rash with eosinophilia and systemic symptoms related to brentuximab vedotin: a report of 2 cases","volume":"6","author":"Ragmanauskaite","year":"2020","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaip.2022.02.004_bib50","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaci.2018.10.030","article-title":"Controversies in drug allergy: testing for delayed reactions","volume":"143","author":"Phillips","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.02.004_bib51","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2133.2006.07238.x","article-title":"Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease","volume":"155","author":"Kano","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2021.11.008","article-title":"Risk of progression to autoimmune disease in severe drug eruption: risk factors and the factor-guided stratification","volume":"142","author":"Mizukawa","year":"2022","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib53","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1111\/1346-8138.15639","article-title":"Autoimmune and inflammatory diseases occur in cases of drug-induced hypersensitivity syndrome but not in suspected cases","volume":"48","author":"Shiiya","year":"2021","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib54","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/archdermatol.2009.195","article-title":"Cytomegalovirus disease during severe drug eruptions: report of 2 cases and retrospective study of 18 patients with drug-induced hypersensitivity syndrome","volume":"145","author":"Asano","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib55","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaad.2018.08.052","article-title":"Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms severity score: a useful tool for assessing disease severity and predicting fatal cytomegalovirus disease","volume":"80","author":"Mizukawa","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib56","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.jaad.2005.03.057","article-title":"Fulminant type 1 diabetes mellitus caused by drug hypersensitivity syndrome with human herpesvirus 6 infection","volume":"54","author":"Chiou","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib57","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3389\/fendo.2019.00474","article-title":"Fulminant type 1 diabetes mellitus caused\u00a0by drug reaction with eosinophilia and systemic symptoms (DRESS): a case report and review of the literature","volume":"10","author":"Zhu","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jaip.2022.02.004_bib58","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.928587","article-title":"A\u00a051-year-old woman with drug-induced hypersensitivity syndrome associated with carbamazepine, reactivation of human herpesvirus 6, and acute liver failure: a case report","volume":"22","author":"Miyasaka","year":"2021","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.jaip.2022.02.004_bib59","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1097\/TP.0000000000001655","article-title":"Acute\u00a0liver failure\/injury related to drug reaction with eosinophilia and systemic\u00a0symptoms: outcomes and prognostic factors","volume":"101","author":"Ichai","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.jaip.2022.02.004_bib60","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jaad.2012.08.009","article-title":"Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan","volume":"68","author":"Chen","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib61","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1093\/ndt\/gfp277","article-title":"A\u00a0case of sulphasalazine-induced DRESS syndrome with delayed acute interstitial nephritis","volume":"24","author":"Augusto","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jaip.2022.02.004_bib62","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.11.2008.1257","article-title":"Dapsone hypersensitivity syndrome causing disseminated intravascular coagulation","volume":"2009","author":"Figtree","year":"2009","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaip.2022.02.004_bib63","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-226461","article-title":"DRESS syndrome-associated acute necrotizing eosinophilic myocarditis with giant cells","volume":"2018","author":"Kowtoniuk","year":"2018","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaip.2022.02.004_bib64","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.jaip.2016.07.005","article-title":"Drug reaction, eosinophilia, and systemic symptoms (DRESS) syndrome associated with allopurinol leading to acute necrotizing eosinophilic myocarditis and death due to papillary muscle rupture","volume":"4","author":"Menter","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.02.004_bib65","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jaad.2012.10.017","article-title":"Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution","volume":"68","author":"Ushigome","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib66","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4103\/0019-5154.91850","article-title":"Dress syndrome with sepsis, acute respiratory distress syndrome and pneumomediastinum","volume":"56","author":"Giri","year":"2011","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib67","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/archderm.145.1.67","article-title":"Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure","volume":"145","author":"Eshki","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib68","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/ced.14572","article-title":"Drug rash with eosinophilia and systemic symptoms complicated by haemophagocytic lymphohistiocytosis: is screening required?","volume":"46","author":"Hussain","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib69","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jaip.2013.04.001","article-title":"Ceftazidime-induced drug reaction with eosinophilia and systemic symptoms (DRESS) complicated by hemophagocytic lymphohistiocytosis","volume":"1","author":"Picard","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.02.004_bib70","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-225528","article-title":"Aggressive treatment in paediatric or young patients with drug-induced hypersensitivity syndrome (DiHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS) is associated with future development of type III polyglandular autoimmune syndrome","volume":"2018","author":"Morita","year":"2018","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaip.2022.02.004_bib71","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/cod.13188","article-title":"Drug reaction with eosinophilia and systemic symptoms\/drug-induced hypersensitivity syndrome (DRESS\/DIHS) caused by levofloxacin in a patient with systemic scleroderma, rheumatoid arthritis, and Sjogren syndrome","volume":"80","author":"Matsumoto","year":"2019","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaip.2022.02.004_bib72","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jaad.2010.12.013","article-title":"Fulminant myocarditis as a late sequela of DRESS: two cases","volume":"65","author":"Bourgeois","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib73","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1016\/j.jaad.2010.11.057","article-title":"A\u00a0review of DRESS-associated myocarditis","volume":"66","author":"Bourgeois","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib74","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000187619","article-title":"Systemic lupus erythematosus presenting with Kikuchi-Fujimoto\u2019s disease as a long-term sequela of drug-induced hypersensitivity syndrome. A possible role of Epstein-Barr virus reactivation","volume":"218","author":"Aota","year":"2009","journal-title":"Dermatology"},{"key":"10.1016\/j.jaip.2022.02.004_bib75","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jaad.2021.03.075","article-title":"Clinical, biochemical, and serologic predictors of drug reaction with eosinophilia and systemic symptoms syndrome: a prospective case-control study","volume":"85","author":"Choudhary","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib76","article-title":"Purpura as an indicator of severity in drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms: evidence from a 49-case series","volume":"36","author":"Takei","year":"2022","journal-title":"J\u00a0Eur Acad Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib77","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/pde.14446","article-title":"Pediatric drug reaction with eosinophilia and systemic symptoms: a systematic review of the literature, with a focus on relapsing cases","volume":"38","author":"Afiouni","year":"2021","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib78","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jaip.2021.07.025","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): series\u00a0of 49 French pediatric cases","volume":"10","author":"Bedouelle","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.02.004_bib79","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/pde.14044","article-title":"Pediatric drug reaction with eosinophilia and systemic symptoms: a systematic review of the literature","volume":"37","author":"Metterle","year":"2020","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib80","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjd.12125","article-title":"A\u00a0multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions","volume":"168","author":"Barbaud","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib81","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/QAD.0b013e3282f7cb60","article-title":"A\u00a0review of drug patch testing and implications for HIV clinicians","volume":"22","author":"Shear","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.jaip.2022.02.004_bib82","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jaip.2020.08.012","article-title":"Early high-dose intravenous corticosteroids rapidly arrest Stevens Johnson syndrome and drug reaction with eosinophilia and systemic symptoms recurrence on drug re-exposure","volume":"9","author":"Lehloenya","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.02.004_bib83","doi-asserted-by":"crossref","first-page":"573573","DOI":"10.3389\/fphar.2020.573573","article-title":"An updated review of the diagnostic methods in delayed drug hypersensitivity","volume":"11","author":"Copaescu","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaip.2022.02.004_bib84","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jaci.2020.04.056","article-title":"Cross-reactivity between vancomycin, teicoplanin and telavancin in HLA-A\u221732:01 positive vancomycin DRESS patients sharing an HLA-class II haplotype","volume":"147","author":"Nakkam","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.02.004_bib85","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/cea.13076","article-title":"Sensitivity and specificity of the lymphocyte transformation test in drug reaction with eosinophilia and systemic symptoms causality assessment","volume":"48","author":"Cabanas","year":"2018","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2022.02.004_bib86","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.jaip.2020.12.052","article-title":"The role of in\u00a0vivo and ex\u00a0vivo diagnostic tools in severe delayed immune-mediated adverse antibiotic drug reactions","volume":"9","author":"Copaescu","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.02.004_bib87","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2332\/allergolint.10-RAI-0260","article-title":"Recognition of immune reconstitution syndrome necessary for better management of patients with severe drug eruptions and those under immunosuppressive therapy","volume":"59","author":"Shiohara","year":"2010","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2022.02.004_bib88","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1001\/jamadermatol.2020.0048","article-title":"Evaluation of cyclosporine for the treatment of DRESS syndrome","volume":"156","author":"Nguyen","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib89","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1001\/jamadermatol.2013.1949","article-title":"A\u00a0case of recalcitrant DRESS syndrome with multiple autoimmune sequelae treated with intravenous immunoglobulins","volume":"149","author":"Singer","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib90","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-242240","article-title":"Successful mepolizumab treatment for DRESS-induced refractory eosinophilic myocarditis and concurrent thyroiditis","volume":"14","author":"Truong","year":"2021","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaip.2022.02.004_bib91","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jaip.2020.09.039","article-title":"Benralizumab for severe DRESS in two COVID-19 patients","volume":"9","author":"Schmid-Grendelmeier","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.02.004_bib92","first-page":"338","article-title":"Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles","volume":"141","author":"Lucena","year":"2011","journal-title":"Gastroenterology (New York, NY 1943)"},{"key":"10.1016\/j.jaip.2022.02.004_bib93","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1016\/j.jaip.2020.05.004","article-title":"HLA-A\u2217 68, -A\u2217 11: 01, and -A\u2217 29: 02 alleles are strongly associated with benznidazole-induced maculopapular exanthema (MPE)\/DRESS","volume":"8","author":"Balas","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.02.004_bib94","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa1213096","article-title":"HLA-B\u2217 13: 01 and the dapsone hypersensitivity syndrome","volume":"369","author":"Zhang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.02.004_bib95","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/FPC.0000000000000306","article-title":"Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B\u221713: 01 allele in the Thai population","volume":"27","author":"Tempark","year":"2017","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jaip.2022.02.004_bib96","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.jid.2018.02.004","article-title":"The function of HLA-B\u221713:01 involved in the pathomechanism of dapsone-induced severe cutaneous adverse reactions","volume":"138","author":"Chen","year":"2018","journal-title":"J\u00a0Investigat Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib97","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/cpt.1375","article-title":"Drug-induced liver injury due to flucloxacillin: relevance of multiple human leukocyte antigen alleles","volume":"106","author":"Nicoletti","year":"2019","journal-title":"Clin Pharmacol Therapeut"},{"key":"10.1016\/j.jaip.2022.02.004_bib98","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ng.379","article-title":"HLA-B5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin","volume":"41","author":"Daly","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaip.2022.02.004_bib99","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jhep.2017.03.010","article-title":"Minocycline hepatotoxicity: clinical characterization and identification of HLA-B\u221735:02 as a risk factor","volume":"67","author":"Urban","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib100","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1001\/archderm.1987.01660330082014","article-title":"Genetic susceptibility to toxic epidermal necrolysis","volume":"123","author":"Roujeau","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib101","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1067\/mjd.2001.117854","article-title":"Fixed drug eruption induced by trimethoprim-sulfamethoxazole: evidence for a link to HLA-A30 B13 Cw6 haplotype","volume":"45","author":"\u00d6zkaya-Bayazit","year":"2001","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib102","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.jid.2019.12.025","article-title":"Association of HLA-A\u221711:01 with sulfonamide-related severe cutaneous adverse reactions in Japanese patients","volume":"140","author":"Nakamura","year":"2020","journal-title":"J\u00a0Investig Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib103","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.jaci.2020.08.003","article-title":"Whole genome sequencing identifies genetic variants associated with co-trimoxazole hypersensitivity in Asians","volume":"147","author":"Wang","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.02.004_bib104","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/hep.31258","article-title":"HLA-B14:01 and HLA-B35:01 are associated with trimethoprim-sulfamethoxazole induced liver injury","volume":"73","author":"Li","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jaip.2022.02.004_bib105","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A\u00a0European study of HLA-B in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jaip.2022.02.004_bib106","doi-asserted-by":"crossref","first-page":"672737","DOI":"10.3389\/fimmu.2021.672737","article-title":"Kinetics of abacavir-induced remodelling of the major histocompatibility complex class I peptide repertoire","volume":"12","author":"Illing","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2022.02.004_bib107","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jaci.2019.09.013","article-title":"Single-cell transcriptomics reveal polyclonal memory T-cell responses in skin with positive abacavir patch test results","volume":"144","author":"Redwood","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.02.004_bib108","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.eplepsyres.2013.05.004","article-title":"Predictive markers for carbamazepine and lamotrigine-induced maculopapular exanthema in Han Chinese","volume":"106","author":"Li","year":"2013","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.jaip.2022.02.004_bib109","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1742-7843.2012.00868.x","article-title":"Association between HLA and Stevens\u2013Johnson syndrome induced by carbamazepine in southern Han Chinese: genetic markers besides B\u22171502?","volume":"111","author":"Shi","year":"2012","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.jaip.2022.02.004_bib110","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1346-8138.2011.01457.x","article-title":"HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population","volume":"39","author":"Niihara","year":"2012","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib111","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/tpj.2013.40","article-title":"HLA-A\u2217 31: 01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis","volume":"14","author":"Genin","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jaip.2022.02.004_bib112","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","article-title":"HLA-A\u22173101 and carbamazepine-induced hypersensitivity reactions in Europeans","volume":"364","author":"McCormack","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.02.004_bib113","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.eplepsyres.2011.08.010","article-title":"Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans","volume":"97","author":"Kim","year":"2011","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.jaip.2022.02.004_bib114","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/cpt.1493","article-title":"Shared genetic risk factors across carbamazepine-induced hypersensitivity reactions","volume":"106","author":"Nicoletti","year":"2019","journal-title":"Clin Pharmacol Therapeut"},{"key":"10.1016\/j.jaip.2022.02.004_bib115","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamadermatol.2013.4114","article-title":"Relationship between the HLA-B\u22171502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"149","author":"Tangamornsuksan","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib116","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4103\/0378-6323.57718","article-title":"Association of HLA-B\u2217 1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians","volume":"75","author":"Mehta","year":"2009","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaip.2022.02.004_bib117","first-page":"1","article-title":"Association between HLA-B alleles and carbamazepine-induced maculopapular exanthema and severe cutaneous reactions in Thai patients","volume":"2018","author":"Sukasem","year":"2018","journal-title":"J\u00a0Immunol Res"},{"key":"10.1016\/j.jaip.2022.02.004_bib118","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"A\u00a0marker for Stevens\u2013Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.jaip.2022.02.004_bib119","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.eplepsyres.2017.05.015","article-title":"Association between the HLA-B alleles and carbamazepine-induced SJS\/TEN: a meta-analysis","volume":"135","author":"Wang","year":"2017","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.jaip.2022.02.004_bib120","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41397-019-0143-8","article-title":"Association of carbamazepine-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis with the HLA-B75 serotype or HLA-B\u221715:21 allele in Filipino patients","volume":"20","author":"Capule","year":"2020","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jaip.2022.02.004_bib121","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1111\/all.13821","article-title":"HLA-B\u2217 57: 01 confers genetic susceptibility to carbamazepine-induced SJS\/TEN in Europeans","volume":"74","author":"Mockenhaupt","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2022.02.004_bib122","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3389\/fphar.2017.00879","article-title":"Association of HLA-A and HLA-B alleles with lamotrigine-induced cutaneous adverse drug reactions in the Thai population","volume":"8","author":"Koomdee","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaip.2022.02.004_bib123","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1111\/epi.13087","article-title":"The HLA-A\u22172402\/Cw\u22170102 haplotype is associated with lamotrigine-induced maculopapular eruption in the Korean population","volume":"56","author":"Moon","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.jaip.2022.02.004_bib124","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.anai.2017.02.011","article-title":"HLA-A\u221731:01 and lamotrigine-induced severe cutaneous adverse drug reactions in a Korean population","volume":"118","author":"Kim","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2022.02.004_bib125","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/FPC.0b013e32832c347d","article-title":"High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients","volume":"19","author":"Kazeem","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jaip.2022.02.004_bib126","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1111\/epi.12217","article-title":"HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese","volume":"54","author":"Cheung","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.jaip.2022.02.004_bib127","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/exd.14240","article-title":"Investigating the association of lamotrigine and phenytoin-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis with HLA-B\u22171502 in Iranian population","volume":"30","author":"Sabourirad","year":"2021","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib128","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.seizure.2020.05.006","article-title":"The association between HLA-A\u221703:01 and HLA-B\u221707:02 alleles and oxcarbazepine-induced maculopapular eruption in the Uighur Chinese population","volume":"81","author":"Zhao","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.jaip.2022.02.004_bib129","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2217\/pgs.09.162","article-title":"Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese","volume":"11","author":"Hung","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jaip.2022.02.004_bib130","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1471-2377-13-75","article-title":"The association between oxcarbazepine-induced maculopapular eruption and HLA-B alleles in a Northern Han Chinese population","volume":"13","author":"Lv","year":"2013","journal-title":"BMC Neurol"},{"key":"10.1016\/j.jaip.2022.02.004_bib131","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.2217\/pgs.13.180","article-title":"Specific HLA types are associated with antiepileptic drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese subjects","volume":"14","author":"Kaniwa","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jaip.2022.02.004_bib132","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/cpt.1190","article-title":"HLA alleles and CYP2C9\u22173 as predictors of phenytoin hypersensitivity in East Asians","volume":"105","author":"Su","year":"2019","journal-title":"Clin Pharmacol Therapeut"},{"key":"10.1016\/j.jaip.2022.02.004_bib133","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/tpj.2016.10","article-title":"Association of HLA-B\u221715:13 and HLA-B\u221715:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population","volume":"17","author":"Chang","year":"2017","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jaip.2022.02.004_bib134","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/j.1528-1167.2008.01719.x","article-title":"Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B\u2217 1502 allele in Thai population","volume":"49","author":"Locharernkul","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.jaip.2022.02.004_bib135","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/FPC.0000000000000211","article-title":"Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population","volume":"26","author":"Tassaneeyakul","year":"2016","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jaip.2022.02.004_bib136","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1111\/bcp.14025","article-title":"High and variable population prevalence of HLA-B\u2217 56: 02 in indigenous Australians and relation to phenytoin-associated drug reaction with eosinophilia and systemic symptoms","volume":"85","author":"Somogyi","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaip.2022.02.004_bib137","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1086\/529382","article-title":"High sensitivity of human leukocyte antigen-b\u2217 5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients","volume":"46","author":"Saag","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaip.2022.02.004_bib138","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B\u2217 5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.02.004_bib139","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","article-title":"Association between presence of HLA-B\u2217 5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir","volume":"359","author":"Mallal","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2022.02.004_bib140","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jaci.2015.03.019","article-title":"Pharmacogenetics of abacavir hypersensitivity: a systematic review and meta-analysis of the association with HLA-B\u221757:01","volume":"136","author":"Sousa-Pinto","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.02.004_bib141","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1089\/aid.2011.0107","article-title":"HLA-dependent hypersensitivity reaction to nevirapine in Chinese Han HIV-infected patients","volume":"28","author":"Gao","year":"2012","journal-title":"AIDS Res Human Retroviruses"},{"key":"10.1016\/j.jaip.2022.02.004_bib142","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/cid\/cit021","article-title":"Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population","volume":"56","author":"Carr","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaip.2022.02.004_bib143","first-page":"1152","article-title":"Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population","volume":"72","author":"Carr","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jaip.2022.02.004_bib144","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/QAD.0b013e32801199d9","article-title":"HLA-Cw8 primarily associated with hypersensitivity to nevirapine","volume":"21","author":"Gatanaga","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.jaip.2022.02.004_bib145","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1097\/01.aids.0000238408.82947.09","article-title":"HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients","volume":"20","author":"Littera","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.jaip.2022.02.004_bib146","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/FPC.0b013e32831d0faf","article-title":"HLA-B\u2217 3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients","volume":"19","author":"Chantarangsu","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jaip.2022.02.004_bib147","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00002030-200501030-00014","article-title":"Predisposition to nevirapine hypersensitivity associated with HLA-DRB1\u22170101 and abrogated by low CD4 T-cell counts","volume":"19","author":"Martin","year":"2005","journal-title":"AIDS (London, England)"},{"key":"10.1016\/j.jaip.2022.02.004_bib148","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1093\/cid\/cix096","article-title":"Association of the HLA-B\u221753:01 allele with drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome during treatment of HIV infection with raltegravir","volume":"64","author":"Thomas","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaip.2022.02.004_bib149","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1346-8138.2010.00921.x","article-title":"Stevens\u2013Johnson syndrome induced by acetazolamide","volume":"38","author":"Her","year":"2011","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib150","article-title":"IL-1 and IL-6 inhibitor hypersensitivity link to common HLA-DRB1\u221715 alleles. medRxiv","author":"Hollenbach","year":"2021","journal-title":"Preprint published online January 17"},{"key":"10.1016\/j.jaip.2022.02.004_bib151","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/cpt.2241","article-title":"Class II HLA variants associate with risk of pegaspargase hypersensitivity","volume":"110","author":"Liu","year":"2021","journal-title":"Clin Pharmacol Therapeut"},{"key":"10.1016\/j.jaip.2022.02.004_bib152","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.2217\/pgs-2019-0087","article-title":"Genes identified through genome-wide association studies of osteonecrosis in childhood acute lymphoblastic leukemia patients","volume":"20","author":"Gagn\u00e9","year":"2019","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jaip.2022.02.004_bib153","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2217\/pgs.15.21","article-title":"Genetic markers associated with cutaneous adverse drug reactions to allopurinol: a systematic review","volume":"16","author":"Jarjour","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jaip.2022.02.004_bib154","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjd.12389","article-title":"HLA-B\u221758:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome\/toxic epidermal necrolysis in a Portuguese population","volume":"169","author":"Gon\u00e7alo","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2022.02.004_bib155","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2133.2012.10894.x","article-title":"Association between HLA-B58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong","volume":"167","author":"Chiu","year":"2012","journal-title":"Br J Dermatol (1951)"},{"key":"10.1016\/j.jaip.2022.02.004_bib156","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/FPC.0b013e32834282b8","article-title":"Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans","volume":"21","author":"Kang","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jaip.2022.02.004_bib157","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fphar.2016.00186","article-title":"HLA-B (\u2217) 58:01 for allopurinol-induced cutaneous adverse drug reactions: implication for clinical interpretation in Thailand","volume":"7","author":"Sukasem","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaip.2022.02.004_bib158","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","article-title":"HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Kaniwa","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jaip.2022.02.004_bib159","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/1756-185X.13143","article-title":"Diagnostic utility of HLA-B\u2217 5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis","volume":"20","author":"Yu","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jaip.2022.02.004_bib160","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1111\/bcp.13989","article-title":"Associations of HLA genotypes with antithyroid drug-induced agranulocytosis: a systematic review and meta-analysis of pharmacogenomics studies","volume":"85","author":"Chen","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaip.2022.02.004_bib161","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/FPC.0000000000000209","article-title":"HLA-DRB1\u221716: 01-DQB1\u221705: 02 is a novel genetic risk factor for flupirtine-induced liver injury","volume":"26","author":"Nicoletti","year":"2016","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jaip.2022.02.004_bib162","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1002\/hep.31538","article-title":"HLA-B\u221735:01 and green tea\u2013induced liver injury","volume":"73","author":"Hoofnagle","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jaip.2022.02.004_bib163","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/tpj.2015.40","article-title":"Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1\u221707:01","volume":"16","author":"Parham","year":"2016","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jaip.2022.02.004_bib164","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/ng.632","article-title":"A\u00a0genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury","volume":"42","author":"Singer","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaip.2022.02.004_bib165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-52619-2","article-title":"Identification of HLA-A\u2217 0 2: 06: 01 as the primary disease susceptibility HLA allele in cold medicine-related Stevens-Johnson syndrome with severe ocular complications by high-resolution NGS-based HLA typing","volume":"9","author":"Nakatani","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaip.2022.02.004_bib166","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41397-018-0052-2","article-title":"Association between HLA-B\u22175901 and methazolamide-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"19","author":"Tangamornsuksan","year":"2019","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jaip.2022.02.004_bib167","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/tpj.2015.25","article-title":"HLA-B\u221759:01: a marker for Stevens-Johnson syndrome\/toxic epidermal necrolysis caused by methazolamide in Han Chinese","volume":"16","author":"Yang","year":"2016","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jaip.2022.02.004_bib168","doi-asserted-by":"crossref","first-page":"109095","DOI":"10.1016\/j.biopha.2019.109095","article-title":"Association of HLA-C\u221703:02 with methimazole-induced liver injury in Graves\u2019 disease patients","volume":"117","author":"Li","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jaip.2022.02.004_bib169","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/j.jaci.2020.10.004","article-title":"Beta-lactam-induced immediate hypersensitivity reactions: a genome-wide association study of a deeply phenotyped cohort","volume":"147","author":"Nicoletti","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.02.004_bib170","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.ajhg.2020.08.008","article-title":"Genome-wide study identifies association between HLA-B(\u2217)55:01 and self-reported penicillin allergy","volume":"107","author":"Krebs","year":"2020","journal-title":"Am J Human Genet"},{"key":"10.1016\/j.jaip.2022.02.004_bib171","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/hep.30660","article-title":"HLA-B\u221735:01 allele is a potential biomarker for predicting polygonum multiflorum\u2013induced liver injury in humans","volume":"70","author":"Li","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jaip.2022.02.004_bib172","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/imj.13575","article-title":"Statin-associated immune-mediated necrotising myopathy: a New Zealand case series showing possible overrepresentation in Pacific Islanders","volume":"48","author":"Woolley","year":"2018","journal-title":"Intern Med J"},{"key":"10.1016\/j.jaip.2022.02.004_bib173","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1007\/s00198-016-3568-9","article-title":"Increased risk of strontium ranelate-related SJS\/TEN is associated with HLA","volume":"27","author":"Lee","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jaip.2022.02.004_bib174","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.2217\/pgs.14.69","article-title":"HLA-B\u221713:01 is associated with salazosulfapyridine-induced drug rash with eosinophilia and systemic symptoms in Chinese Han population","volume":"15","author":"Yang","year":"2014","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jaip.2022.02.004_bib175","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/sj.tpj.6500442","article-title":"Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case\u2013control study","volume":"8","author":"Hirata","year":"2008","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jaip.2022.02.004_bib176","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/sj.tpj.6500458","article-title":"Genome-wide pharmacogenetic investigation of a\u00a0hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis","volume":"8","author":"Kindmark","year":"2008","journal-title":"Pharmacogenomics J"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221321982200126X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221321982200126X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:34:29Z","timestamp":1761975269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221321982200126X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":176,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S221321982200126X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2022.02.004","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-Induced Hypersensitivity Syndrome (DIHS)\/Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Clinical Features and Pathogenesis","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2022.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}